ReShape Lifesciences Share Price OTC Markets
Equities
RSLS
US7611236032
Advanced Medical Equipment & Technology
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
5.09 USD | +23.84% |
|
-.--% | -.--% |
15/05 | ReShape Lifesciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
15/05 | Transcript : ReShape Lifesciences Inc., Q1 2024 Earnings Call, May 15, 2024 |
Sales 2022 | 1.12Cr 94Cr | Sales 2023 | 86.78L 72Cr | Capitalization | 46.24L 39Cr |
---|---|---|---|---|---|
Net income 2022 | -4.6Cr -383.94Cr | Net income 2023 | -1.1Cr -92Cr | EV / Sales 2022 | -0.04 x |
Net cash position 2022 | 36.84L 31Cr | Net cash position 2023 | 41.97L 35Cr | EV / Sales 2023 | 0.05 x |
P/E ratio 2022 |
-0.06
x | P/E ratio 2023 |
-0.13
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 88.83% |
Latest transcript on ReShape Lifesciences
1 day | +23.84% |
Managers | Title | Age | Since |
---|---|---|---|
Paul Hickey
CEO | Chief Executive Officer | 59 | 01/20/01 |
Director of Finance/CFO | 63 | 15/21/15 | |
Dov Gal
CMP | Compliance Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Gary Blackford
BRD | Director/Board Member | 66 | 01/16/01 |
Dan Gladney
CHM | Chairman | 70 | 01/15/01 |
Director/Board Member | 70 | 15/21/15 |
1st Jan change | Capi. | |
---|---|---|
+0.91% | 20TCr | |
+3.74% | 18TCr | |
+28.89% | 15TCr | |
+31.66% | 11TCr | |
+1.18% | 6.43TCr | |
+19.45% | 5.49TCr | |
-2.27% | 4.72TCr | |
-9.28% | 3.68TCr | |
-0.10% | 3.53TCr |
- Stock Market
- Equities
- RSLS Stock
- RSLS Stock